Solifenacin-d5 (succinate) (Synonyms: YM905-d5) |
| Catalog No.GC49196 |
An internal standard for the quantification of solifenacin
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
carbamoylcholine Solifenacin-d5 is intended for use as an internal standard for the quantification of solifenacin by GC- or LC-MS. Solifenacin is a competitive antagonist of M1, M2, and M3 muscarinic acetylcholine receptors (Kis = 25, 125, and 10 nM, respectively, for the human receptors).1 It inhibits calcium mobilization induced by carbamoylcholine in isolated guinea pig detrusor muscle cells (Ki = 4 nM).2 Solifenacin inhibits carbachol-induced contraction of isolated guinea pig urinary bladder smooth muscle. In vivo, solifenacin (0.03-1 mg/kg) inhibits carbachol-induced increases in urinary bladder pressure in anesthetized rats. Formulations containing solifenacin have been used in the treatment of overactive bladder.
1.Hegde, S.S.Muscarinic receptors in the bladder: From basic research to therapeuticsBr. J. Pharmacol.147(2)S80-S87(2006) 2.Ikeda, K., Koboyashi, S., Suzuki, M., et al.M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary glandNaunyn Schmiedebergs Arch. Pharmacol.366(2)97-103(2002)
Average Rating: 5 (Based on Reviews and 18 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *